⚠️☢️🇰🇷#крипто #юкорея #регулирование #биржи
южнокорейский регулятор предупреждает: у криптобирж осталось 2 мес, чтобы зарегистрироваться
Крайний срок - 24 сентября
южнокорейский регулятор предупреждает: у криптобирж осталось 2 мес, чтобы зарегистрироваться
Крайний срок - 24 сентября
⚡️🇺🇸#T #отчетность
AT&T Q221 Earnings:
Revenue: USD44B (est USD42.76B)
Free Cash Flow: USD7B (est USD6.15B)
Raises Year Revenue Growth View Sees: 2-3%
Boosts Year-End HBO MAX Forecast To 70-73M Subscribers
Adj EPS: USD0.89 (est USD0.80)
AT&T Q221 Earnings:
Revenue: USD44B (est USD42.76B)
Free Cash Flow: USD7B (est USD6.15B)
Raises Year Revenue Growth View Sees: 2-3%
Boosts Year-End HBO MAX Forecast To 70-73M Subscribers
Adj EPS: USD0.89 (est USD0.80)
⚡️🇺🇸#LUV #отчетность
Southwest Airlines Q221 Earnings:
Operating Revenue: USD4.01B (est USD3.93B)
Passenger Revenue: USD3.57B (est USD3.56B)
Load Factor: 82.9% (est 80%)
Hopeful To Be Profitable In Q3, Q4
Adj EPS: USD-0.35 (est USD-0.26)
Southwest Airlines Q221 Earnings:
Operating Revenue: USD4.01B (est USD3.93B)
Passenger Revenue: USD3.57B (est USD3.56B)
Load Factor: 82.9% (est 80%)
Hopeful To Be Profitable In Q3, Q4
Adj EPS: USD-0.35 (est USD-0.26)
⚡️💥🇺🇸#MRK
FDA Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma
FDA Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma
⚡️🇺🇸#BX #отчетность
Blackstone Q221 Earnings:
AUM: USD684.0B (est USD665.88B)
Total Segment Revenue: USD2.12B (est USD1.88B)
Fee Related Earnings: USD704.1M (est USD664.4M)
Distributable Income/Share: USD82C (est USD79C)
Blackstone Q221 Earnings:
AUM: USD684.0B (est USD665.88B)
Total Segment Revenue: USD2.12B (est USD1.88B)
Fee Related Earnings: USD704.1M (est USD664.4M)
Distributable Income/Share: USD82C (est USD79C)
⚡️🇺🇸#AAL #отчетность
American Airlines Group Q221 Earnings:
Operating Revenue: USD7.48B (est USD7.48B)
Passenger Revenue: USD6.55B (est USD6.53B)
Load Factor: 77.0%
Adj Loss/Share: USD1.69 (est Loss/Share: USD1.72)
Sees Q3 Capacity: -15% To -20% From 2019
American Airlines Group Q221 Earnings:
Operating Revenue: USD7.48B (est USD7.48B)
Passenger Revenue: USD6.55B (est USD6.53B)
Load Factor: 77.0%
Adj Loss/Share: USD1.69 (est Loss/Share: USD1.72)
Sees Q3 Capacity: -15% To -20% From 2019
⚡️🇺🇸#NEM #отчетность
Newmont Q2
Non-GAAP EPS of $0.83 beats by $0.07; GAAP EPS of $0.80 beats by $0.06.
Revenue of $3.06B (+29.1% Y/Y) misses by $50M.
Newmont Q2
Non-GAAP EPS of $0.83 beats by $0.07; GAAP EPS of $0.80 beats by $0.06.
Revenue of $3.06B (+29.1% Y/Y) misses by $50M.
⚡️🇺🇸#BIIB #отчетность
Biogen Q221 Earnings:
Revenue: USD2.78B (est USD2.62B)
Adj EPS: USD5.68 (est USD4.52)
Sees FY Revenue: USD10.65B To USD10.85B (saw: USD10.45B To USD10.75B)
Still Sees FY Adj EPS: USD17.50 To USD19.00 (est USD18.40)
Go FDA Breakthrough Therapy Designation For Lecanemab
Biogen Q221 Earnings:
Revenue: USD2.78B (est USD2.62B)
Adj EPS: USD5.68 (est USD4.52)
Sees FY Revenue: USD10.65B To USD10.85B (saw: USD10.45B To USD10.75B)
Still Sees FY Adj EPS: USD17.50 To USD19.00 (est USD18.40)
Go FDA Breakthrough Therapy Designation For Lecanemab
⚡️🇺🇸#CROX #отчетность
Crocs Q2
Non-GAAP EPS of $2.23 beats by $0.66; GAAP EPS of $4.93 beats by $3.40.
Revenue of $640.8M (+93.3% Y/Y) beats by $78.19M.
Crocs Q2
Non-GAAP EPS of $2.23 beats by $0.66; GAAP EPS of $4.93 beats by $3.40.
Revenue of $640.8M (+93.3% Y/Y) beats by $78.19M.
⚡️🇺🇸#CLF #отчетность
Cleveland-Cliffs Q2
Non-GAAP EPS of $1.20 misses by $0.31; GAAP EPS of $1.33 misses by $0.20.
Revenue of $5B (+358.7% Y/Y) beats by $50M.
The Company expects third-quarter 2021 adjusted EBITDA2 of approximately $1.8 billion and free cash flow2 generation of $1.4 billion.
Cleveland-Cliffs Q2
Non-GAAP EPS of $1.20 misses by $0.31; GAAP EPS of $1.33 misses by $0.20.
Revenue of $5B (+358.7% Y/Y) beats by $50M.
The Company expects third-quarter 2021 adjusted EBITDA2 of approximately $1.8 billion and free cash flow2 generation of $1.4 billion.